Skip to main content
MyDeficiencies

Chlorthalidone

Thiazide-like Diuretic

Also sold as Thalitone.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Chlorthalidone is barely metabolized, induces or inhibits no CYP450 enzyme, and is cleared largely unchanged by the kidney, so it has none of the hepatic-induction or gut-chelation machinery that drives depletion for many other drugs. Its nutrient effects run through a single, well-characterized route instead: blockade of the thiazide-sensitive Na‑Cl cotransporter (NCC) in the distal convoluted tubule. That mechanism reliably wastes potassium and, more modestly, magnesium; it also disturbs sodium handling in a way that is more dilutional than a true dietary deficiency; and, in the opposite direction, it reduces calcium excretion — a retention effect, not a depletion. Chlorthalidone's roughly 45–60 hour half-life and its higher milligram-for-milligram potency than hydrochlorothiazide (HCTZ) mean these electrolyte effects run larger and more sustained than HCTZ's, a distinction ALLHAT and head-to-head cohort data both confirm directly with chlorthalidone in the studied population.

ATC C03BA04 · also sold as Hygroton and Thalitone · reviewed 2026-09-05, expanded 2026-09-10. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Chlorthalidone in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: 2+ independent Tier A sources, chlorthalidone in the cohort, direct measurement, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: at least one Tier A source with chlorthalidone in the cohort showing a real but bounded effect — a definable subgroup, a functional rather than universal deficit, or a well-evidenced excess/retention risk rather than a deficit.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or a class-level extrapolation (Tier C) where another thiazide — usually HCTZ — has data but chlorthalidone itself does not.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: no color, no tier: no Tier B/C mechanistic or class-extrapolation evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white. A genuine evidence gap, printed as one, never converted into reassurance of safety.

What the research found

Potassium

Red — Severe

See study details

Chlorthalidone reliably and substantially lowers serum potassium through distal sodium-for-potassium exchange, at a magnitude larger than hydrochlorothiazide at comparable blood-pressure-lowering doses.

Full detail and limits

What the grade means here: severe: 2+ independent Tier A sources, chlorthalidone in the cohort, direct measurement, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Renal wasting — severe

Limits on what this shows

  • Key negative/null findings: In ALLHAT, participants who developed hypokalemia did not show significantly higher coronary, stroke, or heart-failure rates than those who stayed normokalemic, and the chlorthalidone hypokalemic subgroup had the lowest all-cause mortality hazard ratio (1.21) of the three drug arms studied. All comparative trials cited here are active-comparator (chlorthalidone vs. HCTZ, amlodipine, or lisinopril), not chlorthalidone vs. no treatment, so these figures quantify relative risk between active drugs rather than absolute risk versus an untreated population.
  • At-risk subgroups: Older adults, low dietary potassium intake, concurrent corticosteroid or laxative use, reduced renal reserve, combination with other potassium-wasting drugs.

Regulatory status

Label warns of hypokalemia and instructs periodic serum electrolyte monitoring; the drug interactions section flags added risk with corticosteroids, ACTH, amphotericin B, and other potassium-depleting agents.

Population evidence

ALLHAT (n=9,159 chlorthalidone-arm participants, normokalemic at baseline): 12.9% developed hypokalemia by year 1 vs. 2.1% with amlodipine and 1.0% with lisinopril; severe hypokalemia (K+ <3.2 mmol/L) occurred in 3.5% vs. 0.3% (amlodipine) and 0.2% (lisinopril). A pooled analysis of 9 head-to-head chlorthalidone-vs-HCTZ trials (n=51,789) found a further serum-potassium reduction of 0.22 mEq/L (95% CI −0.32 to −0.11) with chlorthalidone versus HCTZ; a separate dose-response meta-analysis over 12–52 week trials found −0.40 mEq/L with chlorthalidone vs. −0.24 mEq/L with HCTZ (p=.008). In the CLICK trial (advanced CKD, n=160), hypokalemia likewise occurred more often in the chlorthalidone arm even in a reduced-GFR population.

Mechanism

NCC blockade at the distal convoluted tubule increases distal sodium delivery to the collecting duct, driving ENaC-mediated sodium reabsorption coupled to potassium (and hydrogen) secretion; the long half-life sustains this pressure continuously rather than as a daily pulse.

Counter-evidence held on record

Adding an ACE inhibitor (ramipril) to chlorthalidone attenuated its potassium (and magnesium) loss in one small comparative trial, and a 2023 trial found potassium-magnesium citrate more completely corrected the resulting metabolic picture than potassium chloride alone — indicating the deficit is real but modifiable with co-therapy, not an inevitable, unmanageable effect. This is a genuine renal-wasting effect requiring prescriber-directed monitoring and, when indicated, prescription-strength repletion. This dossier does not recommend an over-the-counter potassium dose — unsupervised high-dose potassium supplementation carries its own cardiac risk and must never be inferred from this entry.

Magnesium

Orange — Moderate

See study details

Chlorthalidone measurably lowers magnesium status, but the population-level shift is modest, with true persistent or functional depletion concentrated in a minority of users.

Full detail and limits

What the grade means here: moderate: at least one Tier A source with chlorthalidone in the cohort showing a real but bounded effect — a definable subgroup, a functional rather than universal deficit, or a well-evidenced excess/retention risk rather than a deficit. Renal wasting — bounded

Limits on what this shows

  • Key negative/null findings: The MRFIT shift (about 1 ppm, roughly a fifth of the reference range) was small for most users, and a persistent circulating deficit was seen in only a minority; the strongest evidence of true tissue depletion came from a single small (n=60) trial, not a megatrial on the scale of ALLHAT.
  • At-risk subgroups: Multi-year use, concurrent loop-diuretic or other magnesium-wasting drugs, poor dietary magnesium intake, refractory hypokalemia.

Regulatory status

Label lists hypomagnesemia among its electrolyte warnings and specifically notes hypomagnesemia can render hypokalemia resistant to potassium repletion alone.

Population evidence

In a 60-patient, one-year comparative trial, adding chlorthalidone to beta-blocker therapy produced a statistically significant fall in serum magnesium plus a positive magnesium-loading test (evidence of true tissue depletion, not only a lab-value shift) that the authors called clinically important. In the Multiple Risk Factor Intervention Trial cohort (diuretic users overwhelmingly on chlorthalidone), diuretic users averaged about 1 ppm lower serum magnesium than non-users, and roughly 15% had persistently low magnesium on two samples drawn about four months apart.

Mechanism

The same NCC blockade that wastes potassium secondarily reduces distal-nephron magnesium reabsorption; chronic volume contraction and secondary hyperaldosteronism compound the effect with long-term use.

Counter-evidence held on record

Ramipril co-therapy blunted chlorthalidone's magnesium loss in the same small comparative trial cited above, and the deficit responded to potassium-magnesium citrate repletion under supervision — again indicating a real, dose- and duration-dependent effect rather than an unavoidable one. Persistent or refractory hypokalemia in a patient on chlorthalidone is a reason to ask a prescriber to check magnesium — not a reason to start a magnesium supplement independently.

Sodium

Orange — Moderate

See study details

Chlorthalidone carries a meaningfully higher risk of hospitalization for hyponatremia than hydrochlorothiazide, but this is a drug-induced disturbance of water and sodium handling concentrated in specific patients — not evidence that the general user needs more dietary sodium.

Full detail and limits

What the grade means here: moderate: at least one Tier A source with chlorthalidone in the cohort showing a real but bounded effect — a definable subgroup, a functional rather than universal deficit, or a well-evidenced excess/retention risk rather than a deficit. Dilutional disturbance — bounded

Limits on what this shows

  • Key negative/null findings: The same cohort study found no significant difference between the two drugs in a composite cardiovascular outcome (adjusted HR 0.93, 95% CI 0.81–1.06), so the electrolyte-hospitalization signal did not translate into a detectable difference in major cardiovascular events in that comparison.
  • At-risk subgroups: Older adults (especially women), the first several weeks of therapy, low body weight, concurrent SSRIs/carbamazepine or other ADH-active drugs, high free-water intake.

Regulatory status

Label lists hyponatremia among its electrolyte warnings and instructs periodic serum electrolyte monitoring.

Population evidence

In a population-based cohort of adults 65+ newly started on a thiazide-type diuretic (n=10,384 chlorthalidone; n=19,489 HCTZ; up to 5 years' follow-up), chlorthalidone carried an adjusted hazard ratio of 1.67 (95% CI 1.24–2.28) for hospitalization with hyponatremia versus HCTZ, alongside a 3.06-fold (95% CI 2.04–4.58) higher hazard for hospitalization with hypokalemia. Direct access to the original journal page for this study was blocked during this review; the figures above are reported as quoted independently by two secondary sources that cite the same study (see Sources, entries flagged accordingly).

Mechanism

Natriuresis from NCC blockade combines with impaired urinary dilution and, in some patients, potassium-depletion-driven ADH release, producing a disturbance that is substantially dilutional/hormonal rather than a simple whole-body sodium deficit.

Counter-evidence held on record

This is an active-comparator finding (chlorthalidone vs. HCTZ, not vs. no diuretic), so it quantifies relative risk between two drugs rather than absolute risk from chlorthalidone alone; the same cohort's null cardiovascular-outcome finding is recorded here as a counterweight against over-reading the electrolyte-hospitalization numbers. Chlorthalidone-associated hyponatremia is usually dilutional and is managed by adjusting or stopping the drug under medical supervision, not by adding dietary salt. Increasing sodium intake on one's own in a hyponatremic patient can be inappropriate or harmful and must never be inferred from this entry.

Calcium

Orange — Moderate

See study details

Chlorthalidone reduces urinary calcium excretion and can raise serum calcium. This is a retention effect, the mechanistic opposite of a depletion, and it is the reason thiazide-type diuretics are used therapeutically to treat calcium-losing kidney stones.

Full detail and limits

What the grade means here: moderate: at least one Tier A source with chlorthalidone in the cohort showing a real but bounded effect — a definable subgroup, a functional rather than universal deficit, or a well-evidenced excess/retention risk rather than a deficit. Retention — opposite of depletion

Limits on what this shows

  • Key negative/null findings: In patients with pre-existing, undiagnosed primary hyperparathyroidism, chlorthalidone's calcium-retaining effect can unmask or worsen hypercalcemia — a clinically relevant scenario, but this is a pre-existing condition being revealed, not chlorthalidone independently causing new metabolic bone disease.
  • At-risk subgroups: Undiagnosed primary hyperparathyroidism, concurrent calcium or vitamin D supplementation, sarcoidosis or other granulomatous disease.

Regulatory status

Label states chlorthalidone "decreases urinary calcium excretion and may cause elevations of serum calcium," listed under precautions — not among nutrients the drug depletes.

Population evidence

This direction is well established pharmacologically and is the basis for using chlorthalidone (and other thiazide-type diuretics) off-label to reduce urinary calcium in patients with idiopathic hypercalciuria and recurrent calcium kidney stones. Two chlorthalidone-specific sources describing the magnitude of this effect in more detail could not be opened directly during this review (both returned access errors), so no specific percentage figure is cited here beyond the label's own language; see Sources for the access-blocked flag.

Mechanism

Enhanced calcium reabsorption in the distal convoluted tubule, partly a direct transport effect and partly secondary to the mild volume contraction thiazide-type diuretics produce, which increases proximal sodium and calcium reabsorption.

Counter-evidence held on record

No counter-evidence located here questions the direction of this effect; it is one of the more mechanistically settled findings in thiazide pharmacology and is deliberately exploited in stone-prevention regimens. This is an excess-risk finding, not a deficiency. Supplementing calcium in a patient on chlorthalidone is the hazard here, not the remedy — mistaking this for a "chlorthalidone depletes calcium" claim, as at least one circulating consumer chart does, points a reader in exactly the wrong direction; see Fails Verification below.

Zinc

Yellow — Low

See study details

Increased urinary zinc loss is documented for hydrochlorothiazide and other diuretics, and the same distal-nephron mechanism is plausible for chlorthalidone, but no study measuring zinc status in chlorthalidone-treated patients specifically was located.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or a class-level extrapolation (Tier C) where another thiazide — usually HCTZ — has data but chlorthalidone itself does not. Class extrapolation — mechanistic only

Limits on what this shows

  • Key negative/null findings: None located specific to chlorthalidone in either direction; the absence of drug-specific data, rather than a null result, is the limiting factor here.
  • At-risk subgroups: Would mirror the magnesium at-risk group if the effect is later confirmed for chlorthalidone: long-term use, poor dietary zinc intake.

Regulatory status

Not mentioned anywhere in chlorthalidone's labeling.

Population evidence

Older studies report increased urinary zinc excretion with hydrochlorothiazide and with hydrochlorothiazide-amiloride combinations. None of the zinc-excretion studies located for this review named chlorthalidone as a study drug, and full-text access to confirm the exact cohort composition of one frequently cited comparative-diuretic zinc study was blocked (see Sources).

Mechanism

Thiazide-type diuretics increase distal tubular flow and may compete for shared renal cation-transport pathways, a mechanism broadly analogous to their magnesium effect — but this has not been demonstrated for chlorthalidone itself.

Counter-evidence held on record

No chlorthalidone-specific human study, positive or null, was located; the entry rests entirely on extrapolation from a different molecule in the same drug class. This is a monitoring-worthy possibility, not a confirmed chlorthalidone effect, and must never be presented to a consumer as an established chlorthalidone deficiency — only as a class-level watch item.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

Chlorthalidone binds the two mitochondrial-matrix carbonic anhydrase isoforms in a cell-free enzyme assay, a real and drug-specific finding, but no study has connected this binding to actual mitochondrial function in a cell, tissue, or patient.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or a class-level extrapolation (Tier C) where another thiazide — usually HCTZ — has data but chlorthalidone itself does not. In vitro binding — theoretical only

Limits on what this shows

  • Key negative/null findings: This is an isolated recombinant-enzyme assay, not a cell or tissue study, and no functional consequence was tested. Whether 120-150 nM affinity produces meaningful inhibition at the free plasma concentrations chlorthalidone actually reaches in patients, given its roughly 75% plasma protein binding and more than 98% erythrocyte sequestration, was not addressed and is not established.
  • At-risk subgroups: None identified for chlorthalidone specifically; a pre-existing mitochondrial disorder would be the theoretical subgroup of concern if this mechanism is ever confirmed clinically.

Regulatory status

Not mentioned anywhere in chlorthalidone's labeling.

Population evidence

No human or animal study measuring mitochondrial function, respiratory capacity, or a mitochondrial enzyme marker in chlorthalidone-treated subjects was located. The only chlorthalidone-specific data bearing on this mechanism is a recombinant-enzyme binding assay: chlorthalidone bound the mitochondrial-matrix isoforms carbonic anhydrase VA and VB with dissociation constants of 150 nM and 120 nM respectively, roughly 10-15-fold weaker than its highest-affinity target, cytosolic carbonic anhydrase II (12 nM), the isoform underlying its diuretic mechanism.

Mechanism

Carbonic anhydrase VA and VB supply bicarbonate to two mitochondrial-matrix enzymes central to intermediary metabolism, pyruvate carboxylase (anaplerosis and gluconeogenesis) and carbamoyl phosphate synthetase I (ureagenesis). Inhibiting these isoforms is the proposed route by which a carbonic-anhydrase-active drug could interfere with mitochondrial metabolic capacity, but this is a proposed route from enzyme pharmacology, not a demonstrated effect of chlorthalidone itself.

Counter-evidence held on record

No chlorthalidone-specific human or animal functional study exists to confirm or refute whether this binding is clinically meaningful, and the affinity for the mitochondrial isoforms is substantially weaker than for the isoform that actually drives the drug's diuretic action. This is a laboratory enzyme-binding fact, not demonstrated mitochondrial injury. It must never be presented as "chlorthalidone damages mitochondria" — it is an unconfirmed, low-probability mechanistic possibility only, and it is not chlorthalidone's known clinical mechanism of action, which remains renal NCC blockade.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Not graded — disclosed evidence gap

See study details

No chlorthalidone-specific human or animal study measuring an oxidative-stress marker was found, and the one drug-specific preclinical finding located points away from, not toward, a pro-oxidant mechanism, so this does not clear even the bar for a theoretical yellow.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Evidence gap — ungraded

Limits on what this shows

  • Key negative/null findings: Not applicable in the ordinary sense; the limiting factor is absence of any chlorthalidone-specific oxidative-stress-marker study, not a located null result. The one located preclinical finding, discussed above, runs counter to a depletion/harm narrative rather than supporting one.
  • At-risk subgroups: Not applicable; no subgroup-level signal exists to bound.
  • Why no grade: Both conditions for UNGRADED are met: no Tier B mechanistic or Tier C class-extrapolation evidence exists to support even a yellow grade for a harm/depletion direction, and no circulating consumer claim exists to rebut as white. This is a genuine evidence gap, not a reassurance that chlorthalidone has no effect on oxidative stress.

Regulatory status

Silent on oxidative stress, free radicals, or antioxidant status in every section of chlorthalidone's labeling reviewed for this dossier.

Population evidence

No human or animal study measuring a validated oxidative-stress marker (malondialdehyde, F2-isoprostanes, superoxide dismutase, glutathione, 8-OHdG) in chlorthalidone-treated subjects was located.

Mechanism

None established. The one chlorthalidone-specific preclinical pharmacology finding located during this review describes chlorthalidone decreasing platelet aggregation and vascular permeability and promoting angiogenesis in a preclinical model, effects generally read as vasculo-protective rather than pro-oxidant; the primary report could not be opened directly (blocked) and is cited by title only, corroborated through a tertiary pharmacology reference that was opened directly. This does not establish a harm-direction mechanism, and a secondary-hyperaldosteronism-to-oxidative-stress pathway that might otherwise be proposed for a volume-contracting diuretic could not be grounded in a source this review actually opened, so it is not asserted here.

Counter-evidence held on record

The only chlorthalidone-specific preclinical vascular pharmacology data located argue against, rather than for, a pro-oxidant mechanism, which is itself the reason this entry is not stretched to a theoretical yellow. An evidence gap is not a safety finding. This entry must never be rendered to a consumer as "chlorthalidone does not cause oxidative stress" — only as "not yet studied in a way that would support a graded claim."

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

See study details

A single small trial of clopamide, a different but pharmacologically related thiazide-type diuretic, found copper shifting in opposite directions across blood compartments; no chlorthalidone-specific copper study exists, and this signal is too thin and too indirect for more than a low-confidence yellow.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or a class-level extrapolation (Tier C) where another thiazide — usually HCTZ — has data but chlorthalidone itself does not. Class extrapolation — mixed signal

Limits on what this shows

  • Key negative/null findings: Red-cell copper, the largest circulating copper pool, showed no significant change in the same trial (p<0.1). The trial studied 8 patients on a molecule other than chlorthalidone; no confirmatory or null chlorthalidone-specific study exists in either direction.
  • At-risk subgroups: Not established for chlorthalidone.

Regulatory status

Not mentioned anywhere in chlorthalidone's labeling.

Population evidence

In an 8-patient, 16-week trial of clopamide 5 mg daily (a sulfonamide-based thiazide-type diuretic grouped with, but not identical to, chlorthalidone), white-blood-cell copper fell sharply, from 13.25 to 1.9 fg/cell (p<0.001), while plasma copper rose significantly (p<0.001) and red-cell copper, the largest circulating pool, was essentially unchanged (p<0.1). No chlorthalidone-specific human copper study was located in this review.

Mechanism

No renal or absorptive mechanism was proposed by the clopamide study's own authors, and no chlorthalidone-specific mechanism has been described elsewhere. The opposite-direction shifts across compartments (white-cell copper down, plasma copper up) argue against a simple loss-of-copper narrative and toward a redistribution effect of uncertain clinical meaning, if the finding replicates at all.

Counter-evidence held on record

This is among the weakest tiers of evidence graded anywhere in this dossier: a different molecule, a single 8-patient trial, and a result that moves in different directions in different blood compartments rather than showing a consistent depletion signal. Do not present this as a chlorthalidone copper-depletion finding. It is an unresolved, different-molecule, small-sample signal that has never been tested in chlorthalidone users, and it must be graded and communicated separately from any iron finding, not merged with one.

Iron

Not graded — disclosed evidence gap

See study details

No mechanism, no drug-specific or class-level study, and no circulating consumer claim linking chlorthalidone to iron status was found. This is a genuine evidence gap, not a finding of safety, and it is graded independently of the Copper entry above.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Evidence gap — ungraded

Limits on what this shows

  • Key negative/null findings: Not applicable; there are no studies to report a null result from.
  • At-risk subgroups: Not applicable; no subgroup-level signal exists to bound.
  • Why no grade: Both conditions for UNGRADED are met: no Tier B mechanistic or Tier C class-extrapolation evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white. Printed here as an evidence gap; not to be read as reassurance that chlorthalidone leaves iron status unaffected.

Regulatory status

Silent on iron in every section of chlorthalidone's labeling reviewed for this dossier.

Population evidence

None located, for chlorthalidone or for the thiazide/thiazide-like diuretic class.

Mechanism

None identified. Chlorthalidone was screened against all nine mechanism classes in this protocol (absorption interference, hepatic-induction catabolism, renal wasting, cofactor antagonism, mitochondrial/conjugation loss, dilutional or hormonal disturbance, microbiome disruption, changed intake, increased utilization); none implicates iron. Its own PK profile shows no chelating, gastric-pH-altering, or iron-transporter-competing mechanism, and its labeling does not associate it with gastrointestinal blood loss, hemolysis, or altered erythropoiesis.

Counter-evidence held on record

None applicable; no claim or mechanism exists on either side of this question for chlorthalidone. An evidence gap is not a safety finding. This entry must never be rendered to a consumer as "chlorthalidone does not affect iron" — only as "not yet studied."

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No chlorthalidone-specific or thiazide-class study of gut microbiome composition, diversity, or function was located. Confounding by the condition being treated, not the drug, is presumed until a study isolates the drug's own effect.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Evidence gap — ungraded

Limits on what this shows

  • Key negative/null findings: Two systematic drug-microbiome studies, one in vitro and one human observational, did not flag chlorthalidone or its drug class among the agents affecting gut bacteria; full compound-level supplementary tables for the in vitro screen were not independently opened for this review and are flagged accordingly in Sources.
  • At-risk subgroups: Not applicable; no subgroup-level signal exists to bound.
  • Confounding by indication: Hypertension itself, and the vascular and renal disease it produces, is an active area of gut-microbiome research independent of any drug used to treat it. Any future microbiome difference observed in chlorthalidone users must be checked against untreated or differently-treated hypertensive controls before being attributed to the drug itself.
  • Why no grade: Both conditions for UNGRADED are met: no Tier B mechanistic or Tier C class-extrapolation evidence exists to support even a yellow grade, and no circulating consumer claim exists to rebut as white. Printed here as an evidence gap; not to be read as reassurance that chlorthalidone leaves the gut microbiome unaffected.

Regulatory status

Silent on the gut microbiome in every section of chlorthalidone's labeling reviewed for this dossier.

Population evidence

Two large systematic drug-microbiome studies were checked directly for this expansion: an in vitro screen of more than 1,000 marketed drugs against 40 human gut bacterial strains, and a multi-cohort human observational study spanning 41 medication categories (general population, inflammatory bowel disease, and irritable bowel syndrome cohorts). Neither named chlorthalidone, nor any thiazide or thiazide-like diuretic, among the agents examined or associated with the microbiome; the second study's strongest associations were with proton-pump inhibitors, metformin, antibiotics, and laxatives, not diuretics of any class.

Mechanism

None identified. Chlorthalidone was screened against all nine mechanism classes in this protocol; mechanism G, microbiome disruption affecting endogenous synthesis, is absent for chlorthalidone specifically. It is present in the broader literature only as a hypertension-and-gut-microbiome research association, a disease-state finding, not a drug effect.

Counter-evidence held on record

None applicable; the two systematic studies checked are absence-of-evidence, not evidence-of-absence, and are reported as such rather than as a null result specific to chlorthalidone. An evidence gap is not a safety finding. This entry must never be rendered to a consumer as "chlorthalidone does not affect the gut microbiome" — only as "not yet studied," and any future finding should be checked against confounding by the underlying hypertensive condition before being attributed to the drug.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery and carriage

Yellow — Low

See study details

Chlorthalidone occupies red-blood-cell carbonic anhydrase at very high affinity, a well-documented pharmacokinetic fact already noted elsewhere in this dossier, but no study has measured whether this affects oxygen delivery or unloading in treated patients, and it is graded independently of ATP production below.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or a class-level extrapolation (Tier C) where another thiazide — usually HCTZ — has data but chlorthalidone itself does not. Mechanistic only — binding fact

Limits on what this shows

  • Key negative/null findings: None located in either direction; this is an evidence gap around a real binding fact, not a null functional result.
  • At-risk subgroups: Not established.

Regulatory status

Labeling describes extensive erythrocyte binding (see this dossier's Protein & erythrocyte binding fact above) but does not address oxygen transport.

Population evidence

Ex vivo human blood studies show more than 98% of chlorthalidone in blood is bound to red cells at therapeutic concentrations, with an association constant for erythrocyte carbonic anhydrase of 2.76×10 6 L/mol, roughly 2,000-fold higher than its association constant for serum albumin (1.18×10 3 L/mol); the two major red-cell carbonic anhydrase isoenzymes (HCA-B and HCA-C) bind with similarly high affinity to each other. No study located has measured hemoglobin-oxygen affinity (P50), arterial-venous oxygen content difference, or tissue oxygenation in chlorthalidone-treated patients.

Mechanism

Erythrocyte carbonic anhydrase catalyzes the carbon-dioxide-bicarbonate interconversion underlying the Haldane effect and buffers the pH shifts that shape the Bohr effect on hemoglobin's oxygen affinity. A drug occupying a large fraction of this enzyme's binding capacity is mechanistically positioned to interact with that system, though no functional consequence has been demonstrated.

Context flag, opposite direction

Chlorthalidone's own volume-contracting diuretic mechanism (already established in this dossier's PK block and its Sodium entry) is, as with diuretics generally, expected to concentrate the formed elements of blood and raise a measured hemoglobin or hematocrit reading as a plasma-volume artifact, not a true increase in oxygen-carrying capacity or red-cell mass. This runs opposite to a carriage deficiency and must not be read as one; it is noted here as context, not as an independent finding, and is not re-graded (see Overlap map).

Counter-evidence held on record

The red-cell binding fact is well established pharmacokinetically but has never been connected to a measured oxygen-transport outcome in chlorthalidone-treated patients. Neither the enzyme-binding fact nor the volume-contraction/hemoconcentration effect is evidence of impaired oxygen delivery, and neither supports a supplement recommendation. An elevated hematocrit reading on chlorthalidone more often reflects reduced plasma volume than any true change in red-cell mass or function.

ATP production

Yellow — Low

See study details

No study has directly measured ATP production, mitochondrial respiration, or cellular energy charge in chlorthalidone-treated patients; the only basis for concern is textbook biochemistry layered onto this dossier's own already-graded potassium and magnesium findings, and it must be read as downstream inference, not new evidence, graded independently of oxygen delivery above.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or a class-level extrapolation (Tier C) where another thiazide — usually HCTZ — has data but chlorthalidone itself does not. Downstream inference — not independent

Limits on what this shows

  • Key negative/null findings: No chlorthalidone study has measured phosphocreatine, lactate/pyruvate ratio, exercise capacity, or any other functional energy-status marker. The ALLHAT hypokalemic subgroup (cited under Potassium) showed no excess mortality relative to normokalemic participants on the same drug, arguing against a clinically detectable population-level energy-metabolism penalty.
  • At-risk subgroups: Would track the existing at-risk groups already listed under Potassium and Magnesium (long-term use, poor dietary intake, concurrent potassium- or magnesium-wasting drugs), not a separate population.

Regulatory status

Not addressed in labeling.

Population evidence

None directly measuring ATP or cellular energy status in chlorthalidone-treated patients. This entry rests entirely on mechanistic inference from findings graded elsewhere in this dossier: the Red-tier Potassium entry (ALLHAT and the head-to-head chlorthalidone trials cited there) and the Orange-tier Magnesium entry (Cocco et al. 1987; the MRFIT cohort).

Mechanism

Magnesium is an obligate cofactor for ATP; the biologically active form of the molecule in every cell is the Mg-ATP complex, and Na‑/K‑-ATPase, the pump most directly stressed by chlorthalidone's own potassium-wasting effect, is itself an ATP-consuming enzyme. A drug that measurably lowers both magnesium and potassium is therefore positioned, in principle, to stress ATP-dependent processes. This is general cell biology applied to this drug's own already-graded electrolyte effects, not a chlorthalidone-specific finding about energy metabolism.

Counter-evidence held on record

This entry is definitionally downstream of, not independent from, the graded Potassium and Magnesium entries; see the Overlap map below for how double counting is avoided. This is theoretical biochemistry layered onto already-graded electrolyte findings, not a new measured effect. It must never be marketed as "chlorthalidone depletes ATP" or "impairs energy production" as a standalone claim, and it must not be merged with the separately graded Oxygen delivery and carriage entry above.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Calcium (as "depletion")

    Where it comes from: Circulating drug-nutrient depletion charts list thiazide diuretics as depleting calcium alongside magnesium and potassium.

    Why it fails: Chlorthalidone's own FDA labeling, and its therapeutic use for hypercalciuria/kidney-stone prevention, show the opposite direction: reduced urinary calcium excretion and calcium retention, not loss. See the graded Orange entry above for the correctly directed finding.

  • Vitamin D

    Where it comes from: Same consumer nutrient-depletion charts list "Vitamin D" alongside calcium, magnesium, and potassium for thiazide diuretics.

    Why it fails: No mechanism or chlorthalidone/thiazide-class human study was found. If anything, the calcium-retention effect argues against a vitamin-D-wasting story, since calcium and vitamin D handling are regulated together in the opposite direction from what the claim implies.

  • Phosphorus

    Where it comes from: Listed on at least one consumer chart alongside calcium, magnesium, and potassium for thiazide diuretics.

    Why it fails: No renal-handling mechanism connects distal NCC blockade to phosphate wasting, and no chlorthalidone or thiazide-class human data were found to support it.

  • Coenzyme Q10

    Where it comes from: Listed for thiazide diuretics on at least one consumer chart.

    Why it fails: CoQ10 depletion is a claim rooted in HMG-CoA reductase (statin) pharmacology. There is no renal-excretion or biosynthesis mechanism connecting a distal-tubule sodium-chloride cotransporter blocker to CoQ10 status, and no chlorthalidone data exist.

  • Vitamin B1 (thiamine)

    Where it comes from: Some general "diuretics" nutrient-depletion charts extend a loop-diuretic (furosemide) thiamine-wasting finding to the entire diuretic category.

    Why it fails: Documented diuretic-associated thiamine loss is a loop-diuretic (furosemide) finding tied to organic-cation-transporter effects in the proximal tubule. Chlorthalidone acts at a different nephron segment through a different transporter, and no chlorthalidone-specific or thiazide-class thiamine data were found.

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Labs

    Serum potassium

    Baseline before starting, recheck at 2–4 weeks, then periodically and after any dose increase or added interacting drug (corticosteroid, laxative, another diuretic).

  • Labs

    Serum magnesium

    Consider checking when potassium is persistently low or resistant to correction, and with multi-year continuous use.

  • Labs

    Serum sodium

    Check at baseline and again within the first few weeks, especially in older adults and women; recheck promptly if confusion, headache, or nausea develop.

  • Labs

    Serum calcium

    A baseline check is reasonable; a persistently elevated result on chlorthalidone should prompt evaluation for undiagnosed primary hyperparathyroidism rather than assumption of a benign drug effect.

  • Labs

    Renal function & volume status

    eGFR/creatinine at baseline and periodically; both diuretic effect and electrolyte risk shift with kidney function, as shown directly in the CLICK trial's advanced-CKD population.

  • Not a deficiency

    Uric acid & glucose

    Also monitored on chlorthalidone (gout flares, altered glucose tolerance). These are clinical outcomes, not nutrient deficiencies, and are out of scope for this dossier's grading.

All references used above
  1. THALITONE (chlorthalidone) tablet — prescribing information. — FDA-approved labeling, NLM DailyMed.
  2. Alderman MH, Piller LB, Ford CE, et al. (ALLHAT Collaborative Research Group). Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in ALLHAT. — Hypertension. 2012;59(5):926–933. Chlorthalidone arm n=9,159. DOI 10.1161/HYPERTENSIONAHA.111.180554.
  3. Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease (the CLICK trial). — N Engl J Med. 2021;385(27):2507–2519, n=160, stage 4 CKD. DOI 10.1056/NEJMoa2110730.Primary NEJM page returned an access error during this review; findings cited here (hypokalemia more frequent with chlorthalidone; hyperkalemia risk not increased) came from a secondary academic commentary (Clinical Kidney Journal) that was opened directly.
  4. Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide: a meta-analysis. — J Hum Hypertens. 2019. 9 head-to-head trials, n=51,789; potassium WMD −0.22 mEq/L (95% CI −0.32 to −0.11) favoring greater decline with chlorthalidone. Chlorthalidone named as a distinguishable arm in all 9 included studies.
  5. Chlorthalidone vs. Hydrochlorothiazide for Treatment of Hypertension (review, citing a dose-response meta-analysis). — Am Fam Physician. 2015;92(11):1015. Reports chlorthalidone −0.40 mEq/L vs. HCTZ −0.24 mEq/L over 12–52 week trials (p=.008), and cardiovascular-outcome and blood-pressure comparisons across chlorthalidone- and HCTZ-specific trial arms.
  6. Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. — Ann Intern Med. 2013;158(6):447–455. Ontario adults 65+, n=10,384 chlorthalidone vs. n=19,489 HCTZ, up to 5 years' follow-up. Adjusted HR for hospitalization with hypokalemia 3.06 (95% CI 2.04–4.58); with hyponatremia 1.67 (95% CI 1.24–2.28); composite cardiovascular outcome HR 0.93 (95% CI 0.81–1.06).The Annals of Internal Medicine page itself returned an access error during this review. The hazard-ratio figures above were confirmed independently from two secondary sources opened directly: an Am J Hypertens 2022 review article and an HCPLive news summary, both quoting this study's numbers identically.
  7. Cocco G, Iselin HU, Strozzi C, Cesana B, Baumeler HR. Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. — Eur J Clin Pharmacol. 1987;32(4):335–338. n=60 (30 beta-blocker alone, 30 beta-blocker plus chlorthalidone), 1-year comparative trial; significant fall in serum magnesium and positive magnesium-loading test with chlorthalidone. DOI 10.1007/BF00543964.
  8. Multiple Risk Factor Intervention Trial (MRFIT) investigators. Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial. — Am J Epidemiol. 1985;122(6):1045–1053. Diuretic users in this cohort were primarily on chlorthalidone; diuretic users averaged about 1 ppm lower serum magnesium than non-users, with about 15% persistently low on repeat sampling.
  9. Šimunić M, et al. Ramipril Decreases Chlorthalidone-Induced Loss of Magnesium and Potassium in Hypertensive Patients. — J Clin Pharmacol. 1995. Cited here only as a counter-evidence/attenuation finding (ACE-inhibitor co-therapy blunting chlorthalidone's electrolyte effect); title and mechanism only.Full text returned an access error during this review; no specific numeric effect size from this study is cited above, only the qualitative direction implied by its title.
  10. Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone. — 2023. Cited here only as counter-evidence that the potassium/magnesium deficit is correctable with an alternative repletion strategy.Full text returned an access error during this review; no specific numeric effect size from this study is cited above, only the qualitative direction implied by its title.
  11. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. — Cited here only to corroborate the direction of the calcium-retention effect; no numeric magnitude is drawn from it.Blocked by the publisher's robots rules during this review; title only, no statistics cited from it.
  12. Effect of Chlorthalidone and Hydrochlorothiazide on 12-Hour vs 24-Hour Urinary Calcium Excretion. — J Urol (AUA Journals). Cited here only to corroborate that chlorthalidone-specific urinary calcium data exist in the literature; no numeric magnitude is drawn from it.Full text returned an access error during this review; title only, no statistics cited from it.
  13. Wester PO. Urinary Zinc Excretion during Treatment with Different Diuretics. — Acta Med Scand. 1980.Full text returned an access error during this review; cohort composition (whether chlorthalidone specifically was among the "different diuretics" studied) could not be confirmed, so this source supports only a general thiazide-class zinc signal, graded Yellow, not a chlorthalidone-specific (Tier A) finding.
  14. Golik A, et al. Hydrochlorothiazide-amiloride causes excessive urinary zinc excretion. — Clin Pharmacol Ther. 1987. Hydrochlorothiazide-specific; chlorthalidone was not in this cohort.
  15. Pharmacokinetics of chlorthalidone: dependence of biological half-life on blood carbonic anhydrase levels. — Eur J Clin Pharmacol. 1980. n=6 volunteers; linear relationship between blood carbonic anhydrase concentration and chlorthalidone half-life.
  16. Chlorthalidone. — StatPearls, NCBI Bookshelf NBK553174. Reference text used for mechanism-of-action and comparative-potency corroboration.
  17. Chlortalidone. — Wikipedia. Used only to cross-check the WHO ATC code (C03BA04) and brand names against DailyMed and product-monograph labeling; not relied on for any clinical claim.
  18. Nutrient Depletion Checklist: Diuretics. — Consumer nutrition source (Tier D), used for the circulating-claim audit only.
  19. Drug Induced Nutrient Depletion Chart. — Consumer/supplement-retailer source (Tier D), used for the circulating-claim audit only.
  20. Baranauskiene L, Škiudaite L, Michailoviene V, Petrauskas V, Matulis D. Thiazide and other Cl-benzenesulfonamide-bearing clinical drug affinities for human carbonic anhydrases. — PLOS ONE. 2021;16(6):e0253608. Chlorthalidone (compound 16) tested by name against all 12 human carbonic anhydrase isoforms; reported Kd 150 nM (CA VA) and 120 nM (CA VB), the mitochondrial-matrix isoforms, versus 12 nM (CA II). DOI 10.1371/journal.pone.0253608. Opened and read in full for this review.
  21. Dieterle W, Wagner J, Faigle JW. Binding of chlorthalidone (Hygroton®) to blood components in man. — Eur J Clin Pharmacol. 1976;10(1):37-42. Ex vivo human blood; more than 98% erythrocyte-bound at therapeutic concentrations, association constant for erythrocyte carbonic anhydrase 2.76×10 6 L/mol versus 1.18×10 3 L/mol for serum albumin. DOI 10.1007/BF00561547. Opened and read in full for this review.
  22. du Preez MJ, Lockett CJ. Effect of clopamide, a thiazide diuretic, on copper and zinc levels in hypertensive patients. — J Am Coll Nutr. 1991;10(1):34-37. n=8, 16-week trial of clopamide (a related but distinct thiazide-type diuretic, not chlorthalidone). White-cell copper fell from 13.25 to 1.9 fg/cell (p<0.001); plasma copper rose (p<0.001); red-cell copper not significantly changed (p<0.1). PMID 2010578.Publisher full text (Taylor & Francis) returned an access error during this review; the statistics above were confirmed from the PubMed-hosted abstract and record, which were opened directly, not from the publisher's full-text page.
  23. Kim SW, Roh J, Park CS. Chlorthalidone Decreases Platelet Aggregation and Vascular Permeability and Promotes Angiogenesis. — Hypertension. 2010. Cited here only to document that a chlorthalidone-specific preclinical vascular pharmacology finding exists, and that it describes a vasculo-protective direction (reduced permeability, promoted angiogenesis) rather than an oxidative-stress-depletion mechanism; this absence of a harm-direction mechanism is part of why Oxidative Stress is graded ungraded rather than yellow in this expansion.Full text returned an access error during this review; title, journal, and general direction of findings were confirmed via DrugBank's pharmacology summary (opened directly), not from the primary journal page. No specific effect size or statistic from this study is cited above.
  24. Chlorthalidone. — DrugBank Online, entry DB00310. Used to corroborate the direction (vasculo-protective, not oxidative-stress-inducing) of chlorthalidone's documented platelet-aggregation and vascular-permeability pharmacology, and to confirm no drug-specific mitochondrial, copper, iron, gut-microbiome, oxygen-delivery, or ATP-production mechanism is described in this reference.
  25. Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. — Nature. 2018;555:623-628. In vitro screen of more than 1,000 marketed drugs against 40 representative human gut bacterial strains. Chlorthalidone does not appear in the accessible article text reviewed for this dossier and is not discussed among the diuretic-class findings; used here as absence-of-evidence for the Gut Microbiome Risk ungraded entry.Full compound-level supplementary tables were not independently opened for this review; the absence noted above reflects the main article text only, not a confirmed exclusion from the underlying screen.
  26. Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. — Nat Commun. 2020;11:362. Three Dutch cohorts (general population n=1,539; inflammatory bowel disease n=544; irritable bowel syndrome with controls n=313) across 41 medication categories. Diuretics, thiazide or otherwise, do not appear among the medication categories examined. Opened and read in full for this review; used as absence-of-evidence for the Gut Microbiome Risk ungraded entry.